Top 25 Companies in Global Non-Invasive Cancer Diagnostics Market: Statistics Report Till 2035

Introduction

The non-invasive cancer diagnostics market includes all diagnostic methods which use non-surgical procedures to identify cancer through blood tests, urine tests, and imaging tests instead of requiring surgical biopsies. The market expansion occurs because of three factors which include the rising worldwide cancer rates and the need for better early diagnosis and the development of liquid biopsy and genomic testing methods and the increasing public knowledge of preventive health techniques. The personalized medicine movement together with targeted therapy development drives higher diagnostic tool usage because these tests provide current patient status and treatment options. The market provides potential through two areas which include the development of multi-cancer early detection (MCED) tests and the application of artificial intelligence for greater accuracy and the rising market presence in developing nations which have better health system resources. The research sector benefits from rising biotechnology investments and partnerships between diagnostic companies and academic research organizations which are driving technological advancement. Government initiatives which include national cancer screening programs and precision medicine funding and advanced diagnostic tool regulatory backing are helping to expand the global market.

 

In June 2025, M42, AstraZeneca, and SOPHiA GENETICS partnered to introduce liquid biopsy infrastructure in the UAE, enabling blood-based cancer profiling, enhancing early detection, precision oncology, and accelerating market growth through advanced non-invasive diagnostic technologies and collaborations.

 

Navigate Future Markets with Confidence: Insights from Spherical Insights LLP

The insights presented in this blog are derived from comprehensive market research conducted by Spherical Insights LLP, a trusted advisory partner to leading global enterprises. Backed by in-depth data analysis, expert forecasting, and industry-specific intelligence, our reports empower decision-makers to identify strategic growth opportunities in fast-evolving sectors. Clients seeking detailed market segmentation, competitive landscapes, regional outlooks, and future investment trends will find immense value in the full report. By leveraging our research, businesses can make informed decisions, gain a competitive edge, and stay ahead in the transition toward sustainable and profitable solutions.

 

Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Non-Invasive Cancer Diagnostics Market.

 

Market Segmentation

Global Non-Invasive Cancer Diagnostics Market Size, Share, and COVID-19 Impact Analysis, By Type (Lung Cancer, Breast Cancer, Solid Tumors, Blood Cancer, Ovarian Cancer, Colorectal Cancer, Other), Product Type (Immunochemistry, Clinical Microbiology, Point of Care Test (POCT), Hematology, Hemostasis), Test Type (Urine Test, Imaging Test, Spectroscopy), Application (Blood, Urine, Saliva), End Users (Hospital and Clinics, Diagnostic Centers, Ambulatory Care, Others), By Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa), Analysis and Forecast, 2026–2035.

 

Non-Invasive Cancer Diagnostics Market Size & Statistics

• The Market Size for Non-Invasive Cancer Diagnostics Was Estimated to be worth USD 172.9 Billion in 2025.
• The Market is Going to Expand at a CAGR of 7.48% between 2026 and 2035.
• The Global Non-Invasive Cancer Diagnostics Market Size is anticipated to reach USD 355.7 Billion by 2035.
• Asia Pacific is expected to grow the fastest during the forecast period in the Non-Invasive Cancer Diagnostics Market.
• North America is expected to generate the highest demand during the forecast period in the Non-Invasive Cancer Diagnostics Market.
   

Regional growth and demand                                   

Asia Pacific is expected to grow the fastest during the forecast period in the non-invasive cancer diagnostics market. The region’s rapid growth is driven by rising cancer prevalence, increasing healthcare investments, and growing demand for early detection through non-invasive technologies such as liquid biopsy and AI-based diagnostics. Countries such as China, India, and Japan are leading growth due to expanding healthcare infrastructure, government screening initiatives, and increasing adoption of precision medicine. Additionally, collaborations between research institutions and diagnostic companies, along with funding and policy support, are accelerating market penetration across the region.

 

In December 2025, Pillar Biosciences and AstraZeneca expanded their liquid biopsy partnership in China, enabling blood-based tumor profiling, improving early detection, accelerating precision oncology adoption, and driving regional market growth.

 

North America is expected to generate the highest demand during the forecast period in the non-invasive cancer diagnostics market. Demand is driven by advanced healthcare infrastructure, high adoption of liquid biopsy and next-generation sequencing technologies, and strong presence of key companies such as Illumina, Inc. and Thermo Fisher Scientific Inc. The United States leads the region due to favorable reimbursement policies, strong R&D investments, and increasing focus on personalized medicine and early cancer detection. Additionally, regulatory support and ongoing clinical trials are accelerating adoption of non-invasive diagnostic solutions.

 

In December 2025, researchers in the United States highlighted that multi-cancer early detection (MCED) liquid biopsy tests could reduce late-stage cancer diagnoses by up to 45%, demonstrating strong potential for non-invasive diagnostics and accelerating market demand. Top of Form Bottom of Form

 

 

Top 10 Trends in the Non-Invasive Cancer Diagnostics Market

• Liquid Biopsy Adoption

• Early Cancer Detection Demand
• Multi-Cancer Early Detection (MCED) Tests
• Artificial Intelligence Integration
• Next-Generation Sequencing (NGS) Advancements
• Precision Medicine Expansion
• Biomarker-Based Diagnostics Growth
• Government Screening Initiatives
• Strategic Partnerships & Investments
• Rising Preference for Non-Invasive Testing

 

1. Liquid Biopsy Adoption
   Liquid biopsy technology enables cancer detection through blood and body fluid tests which eliminates the need for traditional tissue biopsy procedures. The test uses circulating tumor DNA and circulating tumor cells together with other biological markers to determine whether cancer exists and which mutations and disease progression patterns are present. The method provides three main benefits which make it suitable for ongoing treatment assessment and disease recurrence tracking because it involves low risk while producing repeatable results and quick test outcomes. The practice is growing because of expanded clinical testing and successful regulatory processes and the incorporation of new genomic testing methods. Medical facilities are now using liquid biopsy technology as their primary method for cancer diagnosis since it enables them to detect cancer at early stages using non-invasive procedures.
    
2. Early Cancer Detection Demand
   The need for early cancer detection drives market expansion for non-invasive diagnostic testing. Early cancer detection leads to better survival outcomes and easier treatment procedures and decreased healthcare expenses. The rising awareness of screening and preventive healthcare among patients and healthcare professionals and government officials is driving the adoption of advanced diagnostic technologies. Patients prefer non-invasive testing methods which use blood tests and imaging because those methods provide safer emergency procedures. The worldwide rise of cancer cases has created a pressing need for healthcare systems to establish early detection programs which results in high demand for new diagnostic solutions.
    
3. Multi-Cancer Early Detection (MCED) Tests
   Multi-cancer early detection (MCED) tests represent a breakthrough innovation which enables multiple cancer types detection through analysis of a single blood sample. The tests detect cancer signals from multiple body organs by employing advanced genomic and epigenomic technologies which track cancer signals before any symptoms manifest. MCED tests have the potential to revolutionize screening by enabling population-wide cancer detection in a cost-effective and efficient manner. Their development and commercialization progress through ongoing research and clinical trials and partnerships between biotech companies and healthcare providers. MCED tests will become essential elements for future cancer screening programs as accuracy advances and regulatory bodies grant more test approvals.
    
4. Artificial Intelligence Integration
   Artificial intelligence (AI) is playing a crucial role in enhancing the accuracy and efficiency of non-invasive cancer diagnostics. AI algorithms can analyze large volumes of complex data which includes imaging and genomic information and biomarker patterns to achieve accurate identification of early cancer indications. This system enhances diagnostic accuracy while boosting decision-making capabilities and providing medical professionals with expedited test results. AI develops predictive models which estimate cancer risk and treatment success rates.
    
5. Next-Generation Sequencing (NGS) Advancements
   Next-Generation Sequencing (NGS) Advancements The technology of next-generation sequencing (NGS) provides researchers with the ability to perform detailed studies of all genetic alterations and molecular transformations that occur in cancer. The system enables researchers to analyze multiple DNA segments by conducting simultaneous sequencing operations which results in comprehensive information about the characteristics of tumors. The medical field uses NGS technology through liquid biopsy methods to identify genetic changes found in blood samples which helps detect diseases early and choose specific treatment methods. The system achieves improvements in speed and precision and cost efficiency through ongoing technological developments which enhance its availability to healthcare facilities.

 

Empower your strategic planning:

Stay informed with the latest industry insights and market trends to identify new opportunities and drive growth in the non-invasive cancer diagnostics market. To explore more in-depth trends, insights, and forecasts, please refer to our detailed report.

 

Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Non-Invasive Cancer Diagnostics Market.

 

Top 25 Companies Leading the Non-Invasive Cancer Diagnostics Market

• F. Hoffmann-La Roche Ltd
• Illumina, Inc.
• Thermo Fisher Scientific Inc.
• QIAGEN N.V.
• Abbott Laboratories
• Agilent Technologies, Inc.
• Quest Diagnostics Incorporated
• Merck KGaA
• Hologic, Inc.
• Becton, Dickinson and Company (BD)
• GlaxoSmithKline plc (GSK)
• Novartis AG
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• Pfizer Inc.
• Myriad Genetics, Inc.
• Guardant Health, Inc.
• Exact Sciences Corporation
• Foundation Medicine, Inc.
• GRAIL, Inc.
• Bio-Rad Laboratories, Inc.
• Sysmex Corporation
• Biocept, Inc.
• Natera, Inc.
• Siemens Healthineers

 

1. F. Hoffmann-La Roche Ltd

Headquarters: Basel, Switzerland

The company establishes itself as a worldwide authority in the fields of pharmaceutical development and diagnostic research while maintaining strong expertise in cancer treatment and individualized medical services. The company develops its non-invasive cancer detection technologies through its molecular diagnostic tools which include liquid biopsy tests and companion diagnostic systems. Roche develops its medical solutions through three main research areas which focus on early disease identification and ongoing patient assessment and customized therapy recommendation. The company maintains its global leadership position in non-invasive cancer detection technology through its ongoing research activities and corporate partnerships and development of digital health products.

 

2. Illumina, Inc.

Headquarters: California, United States

Illumina, Inc. operates as a top biotechnology firm that focuses on developing next-generation sequencing technology and conducting genomic research. The company enables blood tests to detect genetic mutations which makes it essential for non-invasive cancer diagnostic procedures. The company provides its sequencing technology to customers who need to conduct liquid biopsy tests and identify early signs of cancer. The company works with partners around the world to develop genomic technologies for use in medical practice. Illumina drives development of precision oncology through its continuous product innovation which makes its systems more affordable while enhancing their ability to operate at larger scales.

 

3. Thermo Fisher Scientific Inc.

Headquarters: Massachusetts, United States

The company offers scientific tools and reagents together with diagnostic systems which enable cancer research and cancer detection activities. The company provides NGS and PCR and liquid biopsy technologies which enable doctors to detect cancer through non-invasive testing methods. The organization provides accurate molecular testing services which help doctors perform early diagnosis and monitor treatment progress. The company's extensive product range combined with its dedication to developing new solutions enables medical professionals to implement precision medicine. The company's market growth in non-invasive cancer diagnostics establishes itself as an essential player through its acquisition and partnership strategies that build its operational capacity.

 

4. QIAGEN N.V.

Headquarters: Venlo, Netherlands

The company delivers molecular diagnostic solutions together with sample preparation systems on a worldwide basis. The company enables non-invasive cancer diagnosis through its systems which detect DNA and RNA and protein structures from blood specimens. The company provides its technologies for use in three medical fields: liquid biopsy testing and biomarker discovery and personalized medicine development. QIAGEN works together with pharmaceutical companies to create companion diagnostic tests. The company maintains its research and development activities while advancing its automation capabilities to establish itself as a leading company in precision oncology and worldwide diagnostic markets.

 

5. Abbott Laboratories

Headquarters: Illinois, United States

The healthcare sector is served by Abbott Laboratories which provides diagnostic tools and medical devices and pharmaceutical products. The company delivers advanced diagnostic platforms which enable molecular testing for non-invasive cancer detection and monitoring purposes. The company develops diagnostic solutions which provide fast results and accurate results for medical facilities across the world. The company maintains an expanding market for non-invasive testing because of its innovative approach and extensive distribution system and research funding activities. The company uses integrated systems to enhance healthcare results which establish it as a main force in cancer diagnosis development.

 

Are you ready to discover more about the non-invasive cancer diagnostics market?

The report provides an in-depth analysis of the leading companies operating in the global non-invasive cancer diagnostics market. It includes a comparative assessment based on their product portfolios, business overviews, geographical footprint, strategic initiatives, market segment share, and SWOT analysis. Each company is profiled using a standardized format that includes:

 

Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Non-Invasive Cancer Diagnostics Market.

 

Company Profiles

1. F. Hoffmann-La Roche Ltd

• Business Overview
• Company Snapshot
• Products Overview
• Company Market Share Analysis
• Company Coverage Portfolio
• Financial Analysis
• Recent Developments
• Merger and Acquisitions
• SWOT Analysis

1. Illumina, Inc.
2. Thermo Fisher Scientific Inc.
3. QIAGEN N.V.
4. Abbott Laboratories
5. Agilent Technologies, Inc.
6. Quest Diagnostics Incorporated
7. Merck KGaA
8. Hologic, Inc.
9. Others.

 

Conclusion

The Non-Invasive Cancer Diagnostics Market is experiencing strong growth because of three combined factors which include the increasing global cancer burden and the rising need for early diagnosis and the ongoing development of liquid biopsy and next-generation sequencing and artificial intelligence technologies. The diagnostic methods provide multiple benefits which traditional methods lack because they produce results more quickly and people face reduced danger and doctors can watch how patients evolve through their sickness. The market is growing because patients and healthcare professionals become more aware of medical screening programs which governments support through their investments in precision medicine. The market is developing new opportunities through strategic partnerships and product development while healthcare systems grow in emerging markets. High expenses and complex regulatory requirements present ongoing challenges which current research and technological advancements will resolve in the future. The market will continue to grow because it develops essential methods for cancer diagnosis which help patients worldwide.

 

Our Report

North America Antifungal Drugs Market Size Report 2035
North America Nuclear Medicine Market Size Report 2035
North America Antiepileptic Drugs Market Size Report 2035
Russia Vodka Market Size Report 2035
Australia Farm Tire Market Size Report 2035
 

About the Spherical Insights & Consulting

Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.  Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements. 

 

CONTACT US:

For More Information on Your Target Market, Please Contact Us Below:    

Phone: +1 303 800 4326 (the U.S.)

Phone: +91 90289 24100 (APAC)

Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com

Contact Us: https://www.sphericalinsights.com/contact-us

Follow Us: LinkedIn | Facebook | Twitter